

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

Randomized Trial of Pictorial Cigarette Pack Warnings’ Impact on Smoking Behaviors Study Protocol

Research Team: Noel Brewer (co-PI), Seth Noar (co-PI), Marissa Hall, Humberto Parada, Laura Bach, Kurt Ribisl. UNC Gillings School of Global Public Health.

Contractors: Al Stein-Serrousi, Sean Hanley, Pacific Institute for Research; and Evaluation, Ewald & Wasserman

Funding: The National Cancer Institute and FDA Center for Tobacco Products Award Number P30CA016086-38S2

Clinical Trials Identifier: NCT02247908

University of North Carolina Institutional Review Board Number: 13-2861

21 Contents

22

23 Background 3

24 Study purpose 3

25 Study design 3

26 Participants 4

27 Recruitment and screening 5

28 Procedures 5

29 Measures 7

30 Data analysis 9

31

32

33

34 Background

35
36 The U.S. Food and Drug Administration (FDA) approved 9 new warnings for cigarette packs in
37 June 2011 to better communicate the risks of smoking. A court ruling that struck down the labels
38 criticized FDA for failing to “present any data – much less the substantial evidence required
39 under the federal law – showing that enacting their proposed graphic warnings will accomplish
40 the agency's stated objective of reducing smoking rates.” Our project will address this critique
41 head-on by rigorously testing the impact of the text and graphic warnings on risk perception and
42 smoking behavior.

43
44 While the randomized experiments on candidate warnings have been informative, one limitation
45 is their use of psychological outcomes, such as attitudes or quit intentions, but not smoking
46 behavior. Another is that they typically expose participants to warnings in artificial experimental
47 settings for a short period of time, using much lower frequency and shorter duration of warning
48 exposure than found in the real world. Finally, previous experiments have largely ignored the
49 impact of warnings on vulnerable populations. Research on the impact of cigarette pack
50 warnings currently in use focuses on population-level observational studies of smoking
51 behavior, but these studies are unable to support strong causal inferences. Our study will
52 address these limitations by measuring the impact of warnings on risk perceptions and
53 cessation behaviors, placing warnings on smokers' actual cigarette packs for 4 weeks, and
54 assessing the impact of the warnings on low-income adults, a group with high rates of smoking
55 and thus high risk for harm.

56 Study purpose

57
58 The purpose of this randomized controlled trial is to determine whether graphic health warnings
59 on cigarette packs are more effective than the existing Surgeon General's warning on cigarette
60 packs at encouraging quit attempts. While previous experiments evaluating candidate graphic
61 warnings have been informative, they have used psychological outcomes, such as attitudes or
62 quit intentions, but not actual cessation behavior (e.g., quit attempts). Furthermore, they
63 typically expose participants to warnings in controlled but artificial experimental settings for a
64 short period of time, using much lower frequency and shorter duration of warning exposure than
65 found in the real world. This study addresses these issues by evaluating the impact of warnings
66 on quit attempts by randomly assigning smokers to have their cigarette packs labeled with either
67 a graphic warning or a Surgeon General's warning for four weeks.

68
69 Main hypothesis: Smokers randomized to receive graphic warnings on their cigarette packs will
70 be more likely to report a quit attempt in the 4 weeks of the study than smokers randomized to
71 receive a Surgeon General's label on their cigarette packs.

72
73 Secondary hypothesis: Smokers randomized to receive graphic warnings on their cigarette
74 packs will have higher quit intentions at 4 weeks than smokers randomized to receive a
75 Surgeon General's label on their cigarette packs, controlling for baseline quit intentions.

76 Study design

77
78 This protocol is for a parallel-group, randomized, controlled trial with smokers in Chapel Hill,
79 North Carolina and Oakland, California. The study arms and location are described below.

80

81 Study arms

- 82 1. Experimental: Graphic warnings that include text and an image depicting a health effect
83 of smoking will be applied on labels that cover the top half of the front and back of
84 participants' cigarette packs each week for 4 weeks. The text for these warnings was
85 selected from the 2009 Family Smoking Prevention and Tobacco Control Act and the
86 images were proposed by the FDA. Participants will be randomly assigned to receive
87 one of the following four graphic warnings on their cigarette packs for 4 weeks:
- 88 • Text: "WARNING: Cigarettes are addictive." Image: Man smoking through
89 tracheotomy hole.
 - 90 • Text: "WARNING: Cigarettes causes fatal lung disease." Image: Healthy lungs
91 next to diseased lungs.
 - 92 • Text: "WARNING: Cigarettes cause cancer." Image: Mouth with cancerous lesion
93 on lip.
 - 94 • Text: "WARNING: Smoking can kill you." Image: Woman dying from cancer.
- 95 2. Active Comparator: Labels with Surgeon General's Warning text will be applied to the
96 side of participants' cigarette packs each week for 4 weeks, on top of the Surgeon
97 General's Warning printed by the manufacturer. Participants will be randomly assigned
98 to receive warnings with one of the four Surgeon General's Warnings on their cigarette
99 packs for 4 weeks:
- 100 • SURGEON GENERAL'S WARNING: Smoking Causes Lung Cancer, Heart
101 Disease, Emphysema, and May Complicate Pregnancy.
 - 102 • SURGEON GENERAL'S WARNING: Quitting Smoking Now Greatly Reduces
103 Serious Risks to Your Health.
 - 104 • SURGEON GENERAL'S WARNING: Smoking by Pregnant Women May Result
105 in Fetal Injury, Premature Birth, and Low Birth Weight.
 - 106 • SURGEON GENERAL'S WARNING: Cigarette Smoke Contains Carbon
107 Monoxide.

108
109 Study locations

- 110 1. Prevention Research Center of the Pacific Institute for Research & Evaluation. Oakland,
111 California, United States, 94612
- 112 2. Pacific Institute for Research and Evaluation. Chapel Hill, North Carolina, United States,
113 27514

114 Participants

115
116 Participants are adult cigarette smokers in North Carolina and California. Inclusion and
117 exclusion criteria are described below.

118
119 Inclusion criteria:

- 120 • Be 18 years or older
- 121 • Have smoked at least 100 cigarettes in his or her lifetime
- 122 • Currently smoke cigarettes
- 123 • Be able to read and speak English

124
125 Exclusion criteria:

- 126 • Pregnant women
- 127 • Smokers who smoke exclusively roll-your-own cigarettes
- 128 • Smokers concurrently enrolled in another cessation study

- 129 • Smokers who smoke fewer than 7 cigarettes per week, on average
- 130 • Smokers who live in the same household as someone who has enrolled in the study

131 Recruitment and screening

132
133 PIRE and Ewald & Wasserman, the study contractors, will use recruitment methods that include
134 a study phone number and a website that gives information about the study in written FAQs. To
135 recruit smokers, staff will use Facebook, Craigslist, e-mail lists, in-person recruitment, referrals
136 from local retailers, flyers, yard signs, bus advertisements, and newspaper advertisements. Staff
137 will use a recruiting script to recruit smokers in person, during which smokers may opt to provide
138 contact information to facilitate follow up from staff regarding the study. Smokers will complete
139 an electronic screener on the study website or over the phone with a staff member. After
140 confirming eligibility, study staff will schedule the baseline appointment for eligible smokers. We
141 aim to enroll 2,250 smokers in the trial.

142 Procedures

143 **Cognitive Interviewing Methods:** Staff members from the UNC team will cognitively test the
144 survey instrument with 12-16 smokers prior to the pilot study. Cognitive interviewing participants
145 will be shown a cigarette pack with a graphic warning label and asked to take a survey that asks
146 questions about their smoking behavior and reactions to the label. A UNC research assistant
147 will ask them follow up questions to determine whether participants understand the survey
148 questions and if the survey questions include all appropriate response options. This process will
149 take 45-60 minutes to complete and will be conducted in a private UNC study office. The results
150 from the cognitive interviewing will inform the survey that will be used in the pilot study and full
151 RCT. Participants will be given a \$50 cash incentive for their participation. A second round of
152 cognitive testing will be conducted with 10 current smokers and e-cigarette users. The process
153 will be the same as the first round but will also include questions about e-cigarette use. There
154 are two versions of the interview guide that include different exposures to warning labels on
155 cigarette packs. We will use one guide with half the participants and one guide with the other
156 half of participants. Compensation will also be \$50 for about a 45-60 minute appointment.

157 **Pilot Study:** We will conduct a pilot study with ~50 smokers to confirm the ability to implement
158 all RCT procedures with fidelity. This pilot study will confirm that smokers will complete a 4-
159 week protocol that requires 5 appointments at the study offices (baseline and 4 follow-up
160 appointments). We will make changes as needed to address any problems the pilot identifies.

161 **RCT:** PIRE has offices across the U.S. We chose their offices in Chapel Hill, North Carolina and
162 Oakland, California to be study sites as they represent geographically distinct regions. Both
163 also serve diverse communities with a higher percentage of low-income than the U.S. (Chapel
164 Hill/Durham: 19% low-income, 41% African American, 14% Hispanic; Berkeley/Oakland: 18%
165 low-income, 10% African American; 11% Hispanic). Both offices are accessible by public
166 transportation. Each study site will recruit half of the participants needed for the study.

167 UNC's project manager and Dr. Brewer will receive weekly updates from PIRE about the
168 study. The updates will indicate accrual, number of participants at each study phase, deviations
169 from the study protocol identified during quality checks, and any other problems encountered.
170 The project manager will visit each site regularly during the study to monitor data collection.
171 PIRE will assign supervisors for each site who will conduct quality checks using a checklist. The

172 RCT will first begin at the Chapel Hill site to allow the project manager and PI to closely monitor
173 the initial implementation. The project manager will also travel to Oakland to oversee the initial
174 week of study implementation there.

175 PIRE staff will schedule participants' 5 appointments to visit our offices and ask them how much
176 they smoke in a typical day. If a participant does not bring cigarettes to an appointment, staff will
177 ask them to go purchase the necessary cigarettes and, if necessary, reschedule the
178 appointment within the next 24 hours. PIRE offices in North Carolina and California are
179 centrally located within a 5-10 minute walk of retailers that sell a broad variety of popular
180 cigarette brands.

181 UNC will randomize smokers at each site, *a priori* by order of enrollment, and provide each
182 site's assignments in a spreadsheet. Each smoker will receive the same warning label on their
183 packs throughout their participation in the study.

184 At the baseline appointment, to ensure that we do not enroll participants under age 18, we will
185 visually inspect a valid form of photo ID (e.g., driver's license) for participants who appear to be
186 under age 27. Then, study staff will obtain written informed consent from study participants.
187 Participants will complete two computer surveys at the first appointment, and one survey at the
188 subsequent follow-up appointments. Research staff will ask participants who miss visits to
189 complete the computer survey remotely.

190 At the first four appointments, we will apply the warning labels on participants' cigarette packs
191 (including any currently open packs) using the procedures that we developed in our previous
192 pilot studies. We will remove the top of the cellophane wrapping from the cigarette packs in front
193 of the study participants so that they know that these are fresh cigarette packs that we do not
194 otherwise alter. We will apply self-adhesive labels that have the warnings (printed in color)
195 directly to the packs to prevent smokers from removing the plastic with the label. Graphic labels
196 will go on the top 50% of the front and rear panels of the packs in accordance with the Tobacco
197 Control Act's requirements. Thus, packs will receive 2 (same) labels each – front and back. For
198 hard-pack cigarettes, we will use a utility knife to cut the label horizontally to allow it to separate
199 where the pack opens; this approach was effective in our pilot work. Surgeon General's labels
200 will be applied directly on top of the current Surgeon General's warning.

201 We will then place cigarette packs in sealed bags to preserve freshness. Labeling of cigarettes
202 will take place in person because federal law (Prevent All Cigarette Trafficking Act of 2010)
203 prohibits mailing cigarettes. We will instruct smokers to bring their unsmoked cigarettes to each
204 appointment and conduct this labeling procedure each time (except the final
205 appointment). Participants will receive no instruction about refraining from covering the
206 warnings during the trial, because our intention is to assess the real-world impact of the
207 labels. Participants who stop smoking will remain in the study, continue to attend study
208 appointments, and receive payment for the surveys they complete.

209 Smokers in NC will receive a total of \$185 in incentives (\$50 at baseline; \$30 at week 1; \$30 at
210 week 2; \$30 at week 3; \$45 at week 4). Smokers in CA will receive a total of \$200 in incentives
211 (\$50 at baseline; \$30 at week 1; \$30 at week 2; \$40 at week 3; \$50 at week 4). Our pilot studies
212 suggest that payments of this size motivate participants. A \$30 incentive is enough to pay for 8
213 days' worth of cigarettes, assuming less than a pack of cigarettes per day. Research experts in
214 CA indicated that incentives needed to be greater to account for the increased cost of living. We
215 wish to give participation incentives that reduce the financial burden that purchasing multiple

216 packs at one time may place on lower-income smokers, but also wish to avoid smokers
217 believing that the study is buying them cigarettes or defraying the cost. Thus, we will provide
218 incentives in cash at the appointments, *after* they complete each survey and in envelopes
219 labeled “payment for completing survey.” At the end of the final appointment, each participant
220 will also receive information about local smoking cessation programs.

221 Measures

222

223 Primary outcome measures

- 224 • Quit attempts: The primary outcome is a quit attempt during the 4 weeks of the study,
225 reported at either 1, 2, 3, or 4 weeks. A quit attempt is defined as 24 hours without
226 smoking.

227

228 Secondary outcome measures

- 229 • Quit intentions: Quit intentions will be measured at baseline pretest and posttest, 1, 2, 3,
230 and 4 weeks using the 3-item quit intention scale developed by Klein, Zajac, and Monin
231 (2009).
- 232 • Successful quitting: Successful quitting will be defined as self-reported smoking on 0 of
233 the past 7 days at 4 weeks.
- 234 • Forgoing a cigarette: Forgoing a cigarette will be measured at baseline pretest, 1, 2, 3,
235 and 4 weeks as the frequency of butting out a cigarette or forgoing a cigarette in an
236 effort to smoke less.
- 237 • Positive reinforcement attitudes: Positive reinforcement attitudes smoking attitudes will
238 be measured at baseline pretest and posttest, 1, 2, 3, and 4 weeks using measures
239 adapted from the Smoking Consequences Scale developed by Brandon & Baker (1991).
- 240 • Negative reinforcement attitudes: Negative reinforcement attitudes will be measured at
241 baseline pretest and posttest, 1, 2, 3, and 4 weeks using measures adapted from the
242 Smoking Consequences Scale developed by Brandon & Baker (1991).
- 243 • Perceived likelihood: Perceived likelihood of developing various smoking-related health
244 outcomes will be measured at baseline pretest and posttest, 1, 2, 3, and 4 weeks using
245 measures adapted from Pepper (2013).
- 246 • Conversations about warning labels: Frequency of conversations with other about the
247 warning labels, health effects of smoking and quitting in the past week will be measured
248 at 1, 2, 3, and 4 weeks.
- 249 • Fear: Fear will be measured at baseline posttest, 1, 2, 3, and 4 weeks using 12 items
250 developed by the researcher team and adapted from Nonnemaker et al. (2010), Leshner
251 et al. (2011), Watson et al. (1988), and Keller and Block (1996).
- 252 • Cognitive elaboration: Cognitive elaboration will be measured at 1, 2, 3, and 4 weeks
253 using the Depth of Cognitive Processing Scale (Hammond, Fong, McDonald, Cameron,
254 and Brown, 2003) and measures adapted from Fathelrahman et al (2010).

255

256 Other outcome measures

- 257 • Positive and negative smoker prototypes will be measured at baseline pretest and
258 posttest, 1, 2, 3, and 4 weeks using a shortened version of the smoker prototype scale
259 developed by McCool, Cameron, et al. (2010).
- 260 • Positive and negative e-cigarette user prototypes will be measured at baseline pretest
261 and posttest, 1, 2, 3, and 4 weeks adapting a shortened version of the smoker prototype
262 scale developed by McCool, Cameron, et al. (2010).

- 263 • Quit stage will be measured at baseline pretest and posttest, 1, 2, 3, and 4 weeks using
264 measures adapted from the ITC Quit Intention Scale.
- 265 • Smoking quantity will be measured at baseline pretest, 1, 2, 3, and 4 weeks as the self-
266 reported average number of cigarettes smoked per day during the past week.
- 267 • Implementation intentions will be measured at baseline pretest and 4 weeks to assess
268 how much participants have planned when to quit, how to quit, and how to deal with
269 cravings after quitting.
- 270 • Emotional reactions (i.e., anxiety, disgust, sadness, guilt, anger) will be measured at
271 baseline posttest, 1, 2, 3, and 4 weeks using 12 items developed by the researcher team
272 and adapted from Nonnemaker et al. (2010), Leshner et al. (2011), Watson et al. (1988),
273 and Keller and Block (1996).
- 274 • Perceived understandability will be measured at 1, 2, 3, and 4 weeks using a measure
275 adapted from Cameron, Pepper, and Brewer (2013).
- 276 • Attention/noticing of labels will be measured at baseline posttest, 1, 2, 3, and 4 weeks
277 using measured adapted from Fathelrahman et al. (2010) and Nonnemaker et al. (2010).
- 278 • Pack attitudes will be measured at baseline pretest and 4 weeks using measures
279 adapted from Moodie (2011).
- 280 • Avoidance of the warning label will be measured 1, 2, 3, and 4 weeks using measures
281 adapted from the Population Assessment of Tobacco and Health Study (2014) and the
282 Environics Research Group (2008), as well as measures developed by the research
283 team.
- 284 • Reactance to the warning label will be measured at baseline posttest, 2, and 4 weeks
285 using a scale developed by the research team.
- 286 • Perceived effectiveness of the warning labels will be measured at baseline post-test and
287 4 weeks using measures adapted from Hitchman, Driezen, Logel, Hammond, and Fong
288 (2013), Thrasher et al. (2012) & Cantrell et al.
- 289 • Social reactions to the warning labels will be measured at 1, 2, 3, and 4 weeks using
290 measures developed by the research team to assess the nature, frequency, recipient
291 and mode of communication and regarding conversations about the warning labels,
292 quitting smoking, and the health effects of smoking.
- 293 • Perceived severity of developing various smoking-related health outcomes and of
294 developing quitting side effects will be measured at baseline pretest and posttest, 1, 2, 3,
295 and 4 weeks using measures adapted from Lyna (2002).
- 296 • Anticipated regret of continuing to smoke and anticipated regret of quitting smoking will
297 be measured at baseline pretest and posttest, 1, 2, 3, and 4 weeks using measures
298 developed by the research team.
- 299 • Perceived risks of quitting will be measured at baseline pretest, 1, 2, 3, and 4 weeks
300 using measures adapted from McKee, O'Malley, Salovey, Krishnan-Sarin, and Mazure
301 (2005).
- 302 • Perceived benefits of quitting will be measured at baseline pretest, 1, 2, 3, and 4 weeks
303 using measures adapted from McKee, O'Malley, Salovey, Krishnan-Sarin, and Mazure
304 (2005).
- 305 • Worry about the consequences of smoking will be measured at baseline pretest and
306 posttest, 1, 2, 3, and 4 weeks using measures adapted from Dijkstra (2003), Ranby
307 (2013) and Magnan (2009 and 2013).
- 308 • Subjective norms about smoking cessation will be measured at baseline pretest, 1, 2, 3,
309 and 4 weeks using measures adapted from Armitage (2007) and Von Dras (2004).
- 310 • Self-efficacy to quit smoking will be measured at baseline pretest, 1, 2, 3, and 4 weeks
311 using measures adapted from Armitage (2007).

- 312 • Participants will be randomly assigned to be assessed unprompted recall of the image
313 and/or text of their assigned warning label at 1, 2, 3 or 4 weeks.
- 314 • Participants will be randomly assigned to be assessed recognition of the image and/or
315 text of their assigned warning label at either 1, 2, 3, or 4 weeks.
- 316 • Frequency of e-cigarette use will be measured at 1, 2, 3, and 4 weeks as the number of
317 days of use in the last 7 days.
- 318 • Among never users of e-cigarettes at baseline pretest, initiation of e-cigarette use will be
319 measured at 4 weeks.
- 320 • Use of cessation aids will be measured at baseline pretest, 1, 2, 3, and 4 weeks.
- 321 • The response efficacy of quitting smoking will be measured at baseline pretest and
322 posttest, 1, 2, 3, and 4 weeks using measures developed by the research team.
- 323 • Cons of smoking will be measured at baseline pretest and posttest, 1, 2, 3, and 4 weeks
324 using measures adapted from the Smoking Consequences Scale developed by Brandon
325 & Baker (1991) and items from Velicer (1985).

326 Data analysis

327
328 Power analyses indicated that the target enrollment of 2,250 smokers would provide 80% power
329 to detect a 3% or larger difference in quit attempts, assuming an alpha of .05. We hypothesize
330 that graphic warnings will lead to more quit attempts than text-only warnings. The primary
331 outcome is making any quit attempt during the trial, modeled as a dichotomous outcome.
332 Preliminary analyses will confirm the success of randomization by examining whether the
333 experimental conditions differ by various characteristics (e.g., study site, income, race, Hispanic
334 ethnicity, sexual orientation, sex, age, and education). If conditions differ on any of these
335 variables, main analyses will control for them. Analyses will be intent-to-treat, deeming any
336 missing values at follow-up as being the same as the last observation for adult smokers who
337 drop out during the study and do not complete the final survey. We will also examine the
338 intervention's effects on other secondary study outcomes including intention to quit smoking,
339 and will examine whether poverty status moderates the relationship between pictorial warning
340 assignment and quit attempts. Finally, exploratory analyses will examine time trends in the
341 outcome during the course of the study.
342